Calgary, Alberta – June 8, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel, therapeutics for autism spectrum...
Calgary, Alberta, Canada, May 20, 2026 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 50,001 deferred share units (“DSUs”) to Marvel’s three...
Calgary, Alberta – April 23, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel therapies for autism spectrum...
Calgary, Alberta – April 16, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel therapies for neurological and...
Calgary, Alberta – April 13, 2026 – Marvel Biosciences Corp. (TSXV: MRVL) (“Marvel” or the “Company”) Further tothe Company’s press release of April 8, 2026, announcing its intention to complete a non-brokered private placementoffering of unsecured convertible...
Calgary, Alberta – April 8, 2026 – Marvel Biosciences Corp. (TSXV: MRVL) (“Marvel” or the “Company”) announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (“Debentures”) in the principal amount of...
